Company Description
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.
Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form.
It also has an agreement with The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.
SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Oz Adler |
Contact Details
Address: Tower A, 2nd Floor Tel Aviv, 6971916 Israel | |
| Phone | 972 7 334 47180 |
| Website | scisparc.com |
Stock Details
| Ticker Symbol | SPRC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611746 |
| CUSIP Number | M82618105 |
| ISIN Number | IL0010951403 |
| SIC Code | 5500 |
Key Executives
| Name | Position |
|---|---|
| Oz Adler | Chief Executive Officer |
| Oz Adler | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | 425 | Filing |
| Dec 26, 2024 | 6-K | Report of foreign issuer |
| Dec 17, 2024 | 6-K | Report of foreign issuer |
| Nov 29, 2024 | 425 | Filing |
| Nov 29, 2024 | 6-K | Report of foreign issuer |
| Nov 27, 2024 | 425 | Filing |
| Nov 27, 2024 | 6-K | Report of foreign issuer |
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Oct 23, 2024 | 6-K | Report of foreign issuer |
| Oct 22, 2024 | 6-K | Report of foreign issuer |